Lilly oral obesity drug could get FDA okay in early 2026: report
CEO Dave Ricks said Monday that the company's GLP-1 weight-loss pill orforglipron could receive FDA approval as soon as early ...
Buffalo News1h
5 Best Weight Loss Solutions of 2025: Your Guide to Achieving Lasting Results
Each brand has its own formula for helping users achieve their weight loss goals. Their methods include remote healthcare ...
The Best Obesity Drugs Aren’t Even Here Yet
A new review highlights the future of anti-obesity medications that could outperform today's already blockbuster drugs like ...
FDA Approves Weight-loss Drug Zepbound For Sleep Apnea – Will Insurance Cover This $1000-Per-Month Medication?
Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...
STAT2d
In debate over obesity medications, FDA shifts toward importance of drugs in subtle ways
The changes reflect “a cultural shift” around obesity medications, said Diana Zuckerman, president of the nonprofit National ...
The paradox of RFK Jr.
There is a photo that exemplifies the paradox of Robert F. Kennedy Jr.’s nomination as secretary of the Health and Human ...
Eli Lilly's Zepbound Can Now Be Covered by Medicare to Treat Sleep Apnea
Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and ...
Understanding pros and cons of medical weight loss drugs: What you need to know
As the new year sparks a wave of weight loss resolutions and millions turn to weight loss medications, rising costs and the growing popularity of compounded alternatives have raised critical questions ...
LifeVantage: Bold Move Into The GLP-1 Weight Loss Market Turns Out To Be A Major Winner - Buy
LifeVantage's new MindBody GLP-1 System is riding the coattails of GLP-1 weight loss drugs. See why I rate LFVN stock as a ...
BioSpace4d
Lilly Wins Medicare Coverage for Zepbound in Sleep Apnea
According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to ...
israelnewsonline4d
Medicare may cover Eli Lilly’s Zepbound for sleep apnea: Department of Health and Human Services agency
Both Novo Nordisk and Eli Lilly are studying their weight loss drugs to treat fatty liver disease, chronic kidney disease, ...
Medicare Expands Coverage of Eli Lilly’s Weight-Loss Drug
Eli Lilly’s popular anti-obesity drug Zepbound could get a sales boost after the U.S. Medicare program decided to pay for its use to treat sleep apnea. The Centers f ...